EUR 651.30 For Business Accounts Only

Aspira Womens Health Inc (AWH) - Product Pipeline Analysis, 2021 Update

Summary

Aspira Womens Health Inc (Aspira), formerly Vermillion Inc, is a medical device company that discovers, develops and markets diagnostic and bio-analytical solutions that supports physicians to diagnose, treat and improve gynecologic health outcomes for women. The company’s in vitro diagnostic test OVA1, a simple blood test, which measures the levels of proteins found in the blood and then uses proprietary software to calculate a single score. Its other products includes OVERA, a second-generation biomarker panel intended to maintain OVA1’s high sensitivity while improving specificity; OVA1plus; Aspira GenetiX, a genetic test for gynecologic cancer risk, with a core focus on female reproductive cancers, including breast, ovarian, endometrial, uterine and cervical cancers, and Aspira Synergy, our new decentralized platform and cloud service technology. Its research and development center develops and validates biomarkers and algorithms. The company serves CROs, pharma, biotech and medical device industries across the US. Aspira is headquartered in Austin, Texas, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Aspira Womens Health Inc
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company